Table 2.

Baseline characteristics and outcomes of initially cognitively unimpaired individuals

	ROS/MAP/MARS, N = 1682	NACC, N = 8218	ADNI, N = 490
Sex, n (%)
Female	1272 (75.6%)	5326 (64.8%)	253 (51.6%)
APOE4 status, n (%)
Homozygote	29 (1.7%)	147 (1.8%)	11 (2.2%)
Heterozygote	285 (16.9%)	1747 (21.3%)	131 (26.7%)
Non-carrier	1033 (61.4%)	4634 (56.4%)	348 (71.0%)
Unknown/not genotyped	335 (19.9%)	1690 (20.6%)	Not included
Progressed during the observation period, n (%)
To MCI	462 (27.5%)	1307 (15.9%)	80 (16.3%)
To dementia due to AD	290 (17.2%)	569 (6.9%)	25 (5.1%)
To MCI or dementia due to AD	497 (29.6%)	1579 (19.2%)	80 (16.3%)
Progressed within 8 years, n (%)
To MCI	360 (21.4%)	1305 (15.9%)	71 (14.5%)
To dementia due to AD	170 (10.1%)	568 (6.8%)	14 (2.9%)
To MCI or dementia due to AD	389 (23.1%)	1577 (19.2%)	73 (14.9%)
Age at study entry in years
Mean (SD)	76.2 (7.4)	73.9 (8.2)	74.3 (5.8)
Age category, n (%)
Below 60	Not included	Not included	4 (0.8%)
60 to < 65	56 (3.3%)	1116 (13.6%)	10 (2.0%)
65 to < 70	359 (21.3%)	1593 (19.4%)	91 (18.6%)
70 to < 75	358 (21.3%)	1776 (21.6%)	168 (34.3%)
75 years of age or older	909 (54.0%)	3733 (45.4%)	217 (44.3%)
Years of education
Median (interquartile range)	16 (13–18)	16 (13–18)	16 (14–18)
Follow-up in years
Median (interquartile range)	6 (3–10)	4 (2–6)	3.5 (2–5)

AD Alzheimer’s Disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, APOE4 apolipoprotein E ε4, MCI mild cognitive impairment, N total number of cognitively unimpaired individuals who had at least one post-baseline visit and did not have a diagnosis of MCI or dementia due to AD at study entry in the corresponding cohort, NACC National Alzheimer’s Coordinating Center, ROS/MAP/MARS Religious Orders Study/Memory and Aging Project/Minority Aging Research Study, SD standard deviation